Provectus Biopharmaceuticals

INVESTOR ALERT: Federman & Sherwood Investigates Provectus Biopharmaceuticals, Inc. For Possible Securities Laws Violations

Oklahoma City, OK (May 23, 2014) – The law firm of Federman & Sherwood has launched an investigation of Provectus Biopharmaceuticals, Inc. [NYSE: PVCT] (“Provectus” or “the Company”) for possible violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and/or breaches of fiduciary duty by the Company’s officers and directors.

Federman & Sherwood’s investigation surrounds whether information contained in an analyst’s May 21, 2014 article published in Seeking Alpha is true as alleged. More specifically, it is alleged that the Company failed to commence a Phase 3 randomized, controlled trial of PV-10 after completing its Phase 2 study in 2010. This same article also alleged that Provectus is tied to a stock promotion firm whose recommendations were recently halted by the Securities and Exchange Commission (SEC). Another article by TheStreet.com alleged that although the Company was initially describing its PV-10 oncology drug as a “breakthrough” drug for skin cancer on its website, the description of the drug was later amended to “investigational.” Since the release of these two articles, PVCT shares have dropped over 24%.

If you currently own common stock in Provectus Biopharmaceuticals, Inc., have any information to assist in our investigation, or have questions or concerns regarding this notice or your rights or interests in this matter, please contact Federman & Sherwood, or complete the attached investor certification to be added to our database for this company. Federman & Sherwood has extensive nationwide experience in representing investors in securities, derivative and merger-related shareholder class actions, and has been appointed as lead counsel in multiple complex cases across the country.

Copyright © 2017 Federman & Sherwood. All Rights Reserved.